Cell and Gene Therapy Supply Chain and Raw Materials: Lessons from a Pandemic

The COVID-19 pandemic has had expansive effects on the Gene and Cell Therapy industry, including accelerating the development of viral vector technology. The pandemic has also posed new challenges to the industry's supply chain. Read our newly-released eBook which dives into the post-pandemic supply chain challenges that the industry faces, including an overview of the effects on different supply chain components; Thermo Fisher's CAR T cells manufacturing practices using a GMP-compliant modular workflow that reduces manual cell processing in manufacturing workflows; and an overview of the BioProcess Insider roundtable discussion between different subject matter experts on the post-pandemic effects on the supply chain and what lessons the industry should carry forward to improve supply chain stability and manufacturing practices.